Newsletter

Last night I promised you a big board momentum trade, and here it is.

Get iBio Inc (IBIO) on your screen now.

 

Let me start by saying this... Do not chase a large gap up. We don't expect one, but if there is, be patient.

 

 

 

Now look at the chart below and see the strong sideways consolidation and recent support at $0.35, just below the current price.

 

 

 

The chart shows possible resistance at $0.45, but after that the next stop could be in the mid $0.50's

 

 

We see strong potential gains in IBIO with a solid risk v reward trading profile.

 

 

iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator^(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.

The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at:  www.ibioinc.com

- See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpuf

- See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpuf

iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator^(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.

The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at:  www.ibioinc.com

- See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpuf

iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator^(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.

The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at:  www.ibioinc.com

- See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpuf

iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator^(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.

The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at:  www.ibioinc.com

- See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpuf

 

 

iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator^(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.

 

The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production.

 

Further information is available at their website:  www.ibioinc.com

 

 

iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator^(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.

The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at:  www.ibioinc.com

- See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpuf

Strong News Flow Coming from IBIO

• iBio Appoints Another IPF Expert, Dr. J. Terrill Huggins, to Clinical Advisory Board (Thu 31 Jul)
• iBio Appoints Dr. Richard M. Silver to Clinical Advisory Board (Tue 22 Jul)
• iBio Appoints Dr. Timothy Blackwell to New Clinical Advisory Board (Wed 16 Jul)
• iBio Receives Patent Allowances for Pandemic Influenza Therapeutics (Fri 28 Mar)
• iBio to Present at the 26th Annual ROTH Conference on March 10, 2014 (Wed 12 Mar)
• Phase 1 Clinical Trial Begins for Malaria Vaccine Candidate Based on iBio's Proprietary Technology (Tue 11 Feb)
• iBio Adds Biotherapeutic Product for Treatment of Fibrosis to Its Proprietary Product Pipeline (Fri 31 Jan)
• iBio Receives Allowance of Patent for HPV-Related Cancer Vaccine in China (Wed 22 Jan)
• iBio and Caliber Designate New Fusion Protein as Target Product Under License and Collaboration Agreement (Thu 16 Jan)

 

Make sure you get IBIO on your screen now, this could move fast today.

Disclaimer

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. For full disclaimer click here.
ShiznitStocks.com employees are not registered as an Investment Adviser in any jurisdiction whatsoever. The disclaimer is to be read and fully understood before using our site, or joining our email list. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein.  Instead ShiznitStocks.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. ShiznitStocks.com does not offer such advice or analysis, and ShiznitStocks.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, ShiznitStocks.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, ShiznitStocks.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents have not completed any due diligence or research on the companies advertised herein and disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. ShiznitStocks.com is not responsible for any claims made by the companies advertised herein. ShiznitStocks.com may receive compensation and its employees and affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in ShiznitStocks.com statements and opinions and such statements and opinions cannot be considered independent. ShiznitStocks.com reserves the right to buy and sell shares of the profiled company on the open market before, during or after the release of the company profile. In such an event, ShiznitStocks.com will not update its disclaimer to reflect any shares bought or sold on the open market during the profile coverage. ShiznitStocks.com and its management may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the companies profile. ShiznitStocks.com has not been compensated for the profile of IBIO. ShiznitStocks.com may on occasion accept compensation in restricted or free-trading shares for it's marketing services of the company being profiled, and the third party that might have compensated ShiznitStocks.com may hold free-trading shares of the company being profiled and could very well be selling shares of the companies stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.  If ShiznitStocks.com ever accepts compensation in the form of restricted or free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the current position of those free trading shares received as compensation for our services.